Princeton-based pharmaceutical company Soligenix announced today it has been awarded a contract by the U.S. Department of Health and Human Service's biomedical advanced research and development authority for up to $26.3 million. The project involves development of an oral treatment for a form of toxic radiation exposure.
According to the announcement, the potential five-year contract contains a two-year base period, with two contract options that would extend the contract an additional three years. The total award will support the preclinical and manufacturing development activities necessary to successfully navigate and complete the FDA approval process for use of the company's two-tablet treatment product for gastrointestinal acute radiation syndrome.
Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.View Comment Policy